Literature DB >> 2778651

Pharmacokinetics and saturable renal tubular secretion of zidovudine in rats.

B A Patel1, C K Chu, F D Boudinot.   

Abstract

The purpose of this study was to assess the effects of dose on the pharmacokinetics of zidovudine (3'-azido-3'-deoxythymidine; AZT) in rats. Zidovudine (AZT) was administered intravenously at doses of 10, 50, 100, and 250 mg/kg. Plasma and urine AZT concentrations were determined by HPLC. Plasma AZT concentrations declined rapidly with a terminal half-life ranging from 0.76 h at a dose of 10 mg/kg to 1.58 h at 250 mg/kg. Total clearance (CLT) was similar at the doses of 10 and 50 mg/kg, with values of 2.80 and 2.73 L/h/kg, respectively. However, there was a trend toward nonlinearity at the dose of 100 mg/kg (CLT = 2.13 L/h/kg) and a significant decrease in CLT (1.22 L/h/kg) at the dose of 250 mg/kg. Nonrenal clearance remained unaffected by dose with a mean value of 0.98 L/h/kg. Renal clearance (CLR) was similar at the doses of 10 and 50 mg/kg, with values of 1.89 and 1.37 L/h/kg, respectively. However, significant decreases in CLR were observed at the doses of 100 (CLR = 1.30 L/h/kg) and 250 mg/kg (CLR = 0.57 L/h/kg). The maximum transport capacity (Tmax) and the Michaelis-Menten constant (Km) for renal tubular secretion obtained after simultaneously fitting plasma concentration-time profiles at the four doses to a renal clearance model were 215.5 +/- 82.1 mg/h and 119.3 +/- 80.5 mg/L, respectively, thereby yielding an unbound secretory intrinsic clearance (CLus,int) of 1.81 L/h. The high Tmax and Km values account for the high CLR of AZT and explain the linearity of CLR over a wide range of AZT plasma concentrations.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2778651     DOI: 10.1002/jps.2600780704

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  15 in total

Review 1.  Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development.

Authors:  Jaime A Yáñez; Connie M Remsberg; Casey L Sayre; M Laird Forrest; Neal M Davies
Journal:  Ther Deliv       Date:  2011-05

2.  Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rats.

Authors:  F D Boudinot; S G Smith; E D Funderburg; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1991-04       Impact factor: 5.191

3.  Pharmacokinetics of antiviral polyoxometalates in rats.

Authors:  L Ni; F D Boudinot; S G Boudinot; G W Henson; G E Bossard; S A Martellucci; P W Ash; S P Fricker; M C Darkes; B R Theobald
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Pharmacokinetics of the anti-human immunodeficiency virus nucleoside analog stavudine in cynomolgus monkeys.

Authors:  S Kaul; K A Dandekar
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

5.  Nonlinear disposition of intravenous 2',3'-dideoxyinosine in rats.

Authors:  M G Wientjes; E Mukherji; J L Au
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

6.  Multiple-dose pharmacokinetics of apricitabine, a novel nucleoside reverse transcriptase inhibitor, in patients with HIV-1 infection.

Authors:  Pedro Cahn; Maria Rolon; Isabel Cassetti; LeeAnn Shiveley; Tom Holdich; James Sawyer
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Renal disposition and drug interaction screening of (-)-2'-deoxy-3'-thiacytidine (3TC) in the isolated perfused rat kidney.

Authors:  K R Sweeney; P H Hsyu; P Statkevich; D R Taft
Journal:  Pharm Res       Date:  1995-12       Impact factor: 4.200

8.  Pharmacokinetics of 1-(2-deoxy-2-fluoro-beta-L-arabinofuranosyl)-5-methyluracil (L-FMAU) in rats.

Authors:  J D Wright; T Ma; C K Chu; F D Boudinot
Journal:  Pharm Res       Date:  1995-09       Impact factor: 4.200

9.  Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus.

Authors:  L W Frick; L St John; L C Taylor; G R Painter; P A Furman; D C Liotta; E S Furfine; D J Nelson
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

10.  Effects of gender, pregnancy, and anesthesia on the pharmacokinetics of zidovudine in rats.

Authors:  C S Huang; F D Boudinot; S Feldman
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.